TABLE 1.
Main characteristics of 215 CAP patients and 108 controls found to be positive or negative for S. pneumoniae by blood culturing, LA, and Binax NOW ICT
| Characteristic | Valuea for the following patients:
|
||||||
|---|---|---|---|---|---|---|---|
| Total (n = 215) | S. pneumoniae in blood culture (n = 24)b | LA positive (n = 16) | Strongly ICT positive (n = 28) | Weakly ICT positive (n = 24) | Negative blood culture, LA, and ICT (n = 157) | Control (n = 108) | |
| Age, median (range) yr | 71 (18-96) | 69.5 (31-91) | 67.5 (23-91) | 70.5 (23-91) | 67.5 (31-92) | 72 (18-96) | 68 (33-93) |
| Age of ≥65 yr | 133 (62) | 16 (67) | 10 (62) | 19 (68) | 13 (54) | 97 (62) | 65 (60) |
| Female sex | 102 (47) | 15 (62) | 9 (56) | 14 (50) | 16 (67) | 68 (43) | 44 (40) |
| Score, from Fine et al. (11), median (range) | 83 (18-191) | 84 (31-191) | 82 (31-191) | 88 (53-191) | 81 (31-149) | 83 (18-179) | — |
| Risk classes IV and V | 84 (39) | 11 (46) | 7 (44) | 12 (43) | 8 (33) | 62 (39) | — |
| Length of hospital stay, median (range) days | 4 (1-52) | 5 (1-52) | 5 (1-52) | 5 (1-52) | 4 (1-33) | 4 (1-44) | — |
| Admission to intensive care unit | 10 (4.7) | 3 (12) | 3 (19) | 3 (11) | 2 (8.3) | 5 (3.2) | — |
| 30-day mortality | 5 (2.3) | 1 (4.2) | 1 (6.2) | 1 (3.6) | 0 | 4 (2.5) | — |
| 6-mo mortality | 20 (9.3) | 2 (8.3) | 2 (12) | 2 (7.1) | 1 (4.2) | 17 (11) | — |
| Duration of symptoms before urine collection, median (range) days | 3 (0-35) | 3.5 (0-7) | 4.5 (2-12) | 3 (0-35) | 2.5 (0-10) | 4 (0-30) | — |
| Antibiotic therapy before urine collection | 57 (27) | 7 (29) | 5 (31) | 5 (18) | 2 (8.3) | 48 (31) | 0 |
| Positive urine culture (≥104 CFU ml−1) | 38 (18) | 1 (4.2) | 2c (12) | 4d (14) | 10e (42) | 23 (15) | 35f (32) |
| S. pneumoniae in any culture | 82g (38) | bd | 15h (94) | 27i (96) | 17j (71) | 33k (21) | 5l (4.6) |
| S. pneumoniae in blood | 24 (11) | bd | 13 (81) | 13 (46) | 6 (25) | — | 0 |
| S. pneumoniae in sputum | 34 (16) | 7 (29) | 5 (31) | 9 (32) | 7 (29) | 17 (11) | — |
| S. pneumoniae in nasopharynx | 70 (33) | 17 (71) | 11 (69) | 23 (82) | 15 (62) | 29 (18) | 5 (4.6) |
| LA positive | 16 (7.4) | 13 (54) | bd | 11 (39) | 1 (4.2) | — | 0 |
| Strongly ICT positive | 28 (13) | 13 (54) | 11 (69) | bd | — | — | 0 |
| Weakly ICT positive | 24 (11) | 6 (25) | 1 (6.2) | — | bd | — | 2 (1.9) |
Values are numbers (percentages) of patients, unless otherwise indicated. —, not investigated or by definition 0; bd, by definition, 100%.
Serotypes represented: 1, 3, 7F, 9V, 12F, 14, 16F, 19A, 19F, 22F, 23F, and 33A.
Escherichia coli (n = 1) and Enterococcus faecalis (n = 1).
E. coli (n = 1), Klebsiella species (n = 1), E. faecalis (n = 1), and Streptococcus agalactiae (n = 1).
E. coli (n = 6), Proteus species (n = 1), Enterobacter species (n = 1), mixed Enterobacteriaceae (n = 1), and Staphylococcus aureus (n = 1).
Eleven were treated for urinary tract infections.
Serotypes represented: 1, 3, 4, 6B, 7F, 9N, 9V, 11A, 12F, 14, 16F, 18C, 19A, 19F, 21, 22F, 23F, 31, 33A, 35A, 35B, 38, and 42.
Serotypes represented: 1, 3, 7F, 9V, 14, 19A, 19F, 22F, 23F, and 33A.
Serotypes represented: 1, 3, 6B, 7F, 9N, 9V, 11A, 12F, 14, 19A, 19F, 22F, 23F, 35A, 35B, and 42.
Serotypes represented: 1, 3, 4, 7F, 9N, 9V, 11A, 14, 16F, 18C, and 23F.
Serotypes represented: 3, 4, 7F, 9N, 9V, 11A, 14, 16F, 18C, 19A, 19F, 21, 22F, 23F, 31, and 38.
Serotypes represented: 3, 6B, 11A, 19F, and 23A.